JP4480398B2 - ウイルス、ウイルス分離株及びワクチンの製造方法 - Google Patents
ウイルス、ウイルス分離株及びワクチンの製造方法 Download PDFInfo
- Publication number
- JP4480398B2 JP4480398B2 JP2003549527A JP2003549527A JP4480398B2 JP 4480398 B2 JP4480398 B2 JP 4480398B2 JP 2003549527 A JP2003549527 A JP 2003549527A JP 2003549527 A JP2003549527 A JP 2003549527A JP 4480398 B2 JP4480398 B2 JP 4480398B2
- Authority
- JP
- Japan
- Prior art keywords
- influenza
- cells
- sialyltransferase
- influenza virus
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title claims description 29
- 238000004519 manufacturing process Methods 0.000 title claims description 23
- 241000700605 Viruses Species 0.000 title abstract description 70
- 239000002245 particle Substances 0.000 claims abstract description 92
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 89
- 238000000034 method Methods 0.000 claims abstract description 67
- 206010022000 influenza Diseases 0.000 claims abstract description 63
- 238000012258 culturing Methods 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 198
- 108090000141 Sialyltransferases Proteins 0.000 claims description 62
- 102000003838 Sialyltransferases Human genes 0.000 claims description 61
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 150000007523 nucleic acids Chemical class 0.000 claims description 28
- 101710154606 Hemagglutinin Proteins 0.000 claims description 16
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 16
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 16
- 101710176177 Protein A56 Proteins 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 210000005260 human cell Anatomy 0.000 claims description 11
- 230000000890 antigenic effect Effects 0.000 claims description 10
- 241000701161 unidentified adenovirus Species 0.000 claims description 9
- 102000005348 Neuraminidase Human genes 0.000 claims description 5
- 108010006232 Neuraminidase Proteins 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 claims 5
- 230000001902 propagating effect Effects 0.000 abstract description 14
- 230000013595 glycosylation Effects 0.000 abstract description 8
- 238000006206 glycosylation reaction Methods 0.000 abstract description 8
- 230000003612 virological effect Effects 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 20
- 239000013612 plasmid Substances 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 15
- 241000282412 Homo Species 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 241000271566 Aves Species 0.000 description 13
- 235000013601 eggs Nutrition 0.000 description 13
- 239000000185 hemagglutinin Substances 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 102000004357 Transferases Human genes 0.000 description 10
- 108090000992 Transferases Proteins 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000000644 propagated effect Effects 0.000 description 10
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 9
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 8
- 102000003951 Erythropoietin Human genes 0.000 description 8
- 108090000394 Erythropoietin Proteins 0.000 description 8
- 229940105423 erythropoietin Drugs 0.000 description 8
- 230000002018 overexpression Effects 0.000 description 8
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 8
- 102000003886 Glycoproteins Human genes 0.000 description 7
- 108090000288 Glycoproteins Proteins 0.000 description 7
- 229930193140 Neomycin Natural products 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 229960004927 neomycin Drugs 0.000 description 7
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- 101710186708 Agglutinin Proteins 0.000 description 4
- 101710146024 Horcolin Proteins 0.000 description 4
- 101710189395 Lectin Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 101710179758 Mannose-specific lectin Proteins 0.000 description 4
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 4
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 239000000910 agglutinin Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 150000002270 gangliosides Chemical class 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000007918 pathogenicity Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000004114 suspension culture Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 241001505332 Polyomavirus sp. Species 0.000 description 2
- 240000006028 Sambucus nigra Species 0.000 description 2
- 235000003142 Sambucus nigra Nutrition 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108010066342 Virus Receptors Proteins 0.000 description 2
- 102000018265 Virus Receptors Human genes 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000008995 european elder Nutrition 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000002482 oligosaccharides Polymers 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 108010057856 Adenovirus E2 Proteins Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101150039660 HA gene Proteins 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 229940124873 Influenza virus vaccine Drugs 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241001521394 Maackia amurensis Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241001113283 Respirovirus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000725681 Swine influenza virus Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000013354 cell banking Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 108010056268 sialyloligosaccharide receptor Proteins 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Description
α2,6シアリルトランスフェラーゼをコードしている配列を含む断片を、プラスミドpGST-Gal(アムステルダム自由大学のI. van Die博士からご恵与いただいた;前記プラスミドは、ラットα2,6シアリルトランスフェラーゼをコードする全cDNA配列(GenBankアクセッション番号M18769)を含むpBR322のバックボーンから構成される)をEcoRIで消化することによって得た。前記断片を、標準手順に従って、T4 DNAポリメラーゼによって平滑末端にした。ゲルで精製した後、α2,6シアリルトランスフェラーゼをコードする断片を、pcDNA2000/Hygro(国際公開第00/63403号に記載されているプラスミドpcDNA2000/Hyg(-)とも呼ばれている)にライゲーションし、標準実験法に従って、PmeIで直線化し、脱リン酸化し、ゲルで精製した。生じたプラスミドを、pα2,6ST2000/Hygroと名付けた(図1)。
最初に、PER.C6-EPOを、他の目的のために、すなわちエリスロポエチン(erythropoietin、EPO)の糖鎖形成に重点を置いた実験のために精製した。EPOは、赤血球生産の促進に関与するタンパク質であり、その活性は、生体内での機能性についてそのシアル酸の含量に依存するところが大きい。PER.C6-EPO細胞系は、PER.C6の誘導体であり、ヒトEPOタンパク質を過剰発現させる(細胞について、国際公開第00/63403号に記載されている)。この細胞系がEPOを生産するという事実は、本発明において重要であるとは考えられない。PER.C6-EPO細胞を培養し、該細胞を、以下に記載したとおりにpα2,6ST2000/Hygroでトランスフェクションした。
ヒトα2,6シアリルトランスフェラーゼの完全長cDNA(GeneBankアクセッション番号:14735135)を含むPCR断片を、当業者に既知である方法を用いたヒトcDNAライブラリーによるポリメラーゼ連鎖反応(Polymerase Chain Reaction、PCR)によって得た。増幅に使用したプライマー(センス:5'-TTT TTT GGA TCC ATG ATT CAC ACC AAC CTG AAG AAA AAG-3'、アンチセンス:5'-TTT TTT CTT AAG TTA GCA GTG AAT GGT CCG GAA GC-3')は、センス・プライマーではBamHI、アンチセンス・プライマーではAflIIによる消化をそれぞれ可能にする5'末端部をさらに含む。PCR産物を、アガロースゲル電気泳動によって精製し、BamHI及びAflIIで消化し、続いてpcDNA2000/Hygro(国際公開第00/63403号には、pcDNA2000/Hyg(-)と記載されている)及びpcDNA2000/Neo(このベクターは、基本的にはpcDNA2000/Hyg(-)と同様に、pcDNA2000/DHFRから構築され、その詳細については、国際公開第00/63403号に記載されている)にクローニングした。このために、pcDNA2000/Hygro及びpcDNA2000/NeoもBamHI及びAflII制限酵素で消化した。配列と正確にクローニングされていることを、分子生物学分野の当業者に既知である標準手順に従って、二重鎖配列を決定することによってチェックした。生じたプラスミドを、pα2,6STcDNA2000/Hygro(図2A)及びpα2,6STcDNA2000/Neo(図2B)と名付けた。それらは、拡張したCMVプロモーター(国際公開第00/63403号参照)の制御下のヒトα2,6シアリルトランスフェラーゼをコードする核酸を含む。さらに、前記プラスミドはそれぞれ、プラスミドがそのゲノムに安定した様態で組み込まれているクローンを選択するのに用いるネオマイシン及びハイグロマイシンに対する耐性を与える。
40枚の組織培養シャーレ(直径10cm)に、シャーレ1枚当たり約200万-300万個のPER.C6細胞系の細胞を播き、37℃、10%CO2で一晩中保持した。次の日、メーカーのプロトコールと当業者に既知の標準培養手順に従って、リポフェクトアミン(Gibco)で細胞にトランスフェクションした。20枚のシャーレを、それぞれ5μgのpα2,6STcDNA2000/Neoでトランスフェクションした。トランスフェクションしていない細胞を有する別の20枚のシャーレは、ネオマイシンによる死滅及びトランスフェクション効率用のネガティブコントロールとなる。次の日、ネオマイシン(0.5mg/ml)を、FBSを含む培地に溶解して、適切なシャーレに添加した。細胞を、4-5週間にわたってインキュベートし、選択剤を追加した新鮮な培地で細胞を定期的に洗浄した。毎日、細胞が死んでいるかどうか観測し、ネオマイシン及びハイグロマイシン選択マーカーを宿すプラスミドを与えられていないネガティブコントロールと比較した。エリスロポエチン過剰発現細胞系及び抗体過剰発現細胞系について国際公開第00/63403号に概ね記載されているとおりに大きく成長したクローンを採取し、継代培養した。
実験を行って、PER.C6細胞の感染に対する感受性をPER.C6−α2,6STのものと比較した。PER.C6及びPER.C6−α2,6STの懸濁培養物を、4mMのL−グルタミン(Gibco)を追加した血清のないExCell 525培地(JRH Biosciences)にて、37℃、10%CO2で、490cm2の組織培養回転ボトル内で、1rpmで連続回転させながら培養した。以下に記載されている手順を、報告した全てのインフルエンザ感染に適用した。感染の日に、細胞を、6ウェルのプレートに、1x106個の細胞/mlの密度で、2mg/mlのPen/Strep(Gibco)、200ng/mlのファンギゾン(Gibco)及び3μg/mlのトリプシン−EDTA(Gibco)を含む最終容積が2mlの血清のない培地に播いた。初代分離株のウイルス接種材料及びPER.C6順応バッチ(初代分離株に由来し、PER.C6細胞上で1継代、継代培養した)で細胞を感染させた。使用した初代分離株は、A/Netherlands/002/01(H1N1、A/New Caledoniaと類似、ロッテルダム大学のA. Osterhaus博士・教授からご恵与いただいた)。バッチを両方とも、100倍(容積/容積)希釈して使用した。感染した細胞を、35℃、10%CO2で、静置培養で6日間保持した。ウイルス上清を実験を通じて回収し、続いて清浄にした。室温で、5000rpmで5分間微量遠心して細胞をペレットにすることによって、清浄を行った。細胞のペレットを、以下に記載されている直接免疫蛍光アッセイによって分析した。上清を、新しいエッペンドルフ・チューブに移し、液体窒素で急速に凍結させ、プラーク・アッセイ(下記参照)に使用するまで、-80℃で保存した。
インフルエンザウイルスの感染を検出するために、直接免疫蛍光(immunofluorescence、I.F.)アッセイを、IMAGEN(登録商標)インフルエンザウイルスA及びBキット(Dako)を用いて、供給業者が提供するプロトコールに従って、感染した細胞(上記参照)で行った。以下に簡潔に記載する。感染した細胞を5分間遠心した。上清を除去し、ペレットをPBSに再懸濁した。これを二回繰り返して、細胞を完全に洗浄した。洗浄した細胞のペレットをPBSに再懸濁し、20μlの細胞懸濁液を、I.F.スライドの2個のウェルにそれぞれ添加した。これを、室温で乾燥させた。20μlのアセトンを各ウェルに添加することで細胞を固定し、風乾した。各ウェルに、20μlの適切なIMAGENインフルエンザ試薬(すなわち、標識抗体特異的インフルエンザA又はB)を添加した。次に、スライドを、37℃で15分間、湿らせたティッシュペーパー上でインキュベートした。過剰な試薬を、PBSで洗い流し、次にPBSで5分間すすいだ。スライドを室温で風乾した。IMAGEN封入液を各ウェルに一滴添加し、カバーガラスをスライドの上に置いた(これを、少量のマニキュア液で所定の位置に固定した)。サンプルを、落射蛍光照射を用いて顕微鏡で観察した。感染した細胞は、明るい淡黄緑色の蛍光を特徴とする。ネガティブ(赤)細胞と比較して、ポジティブ(蛍光緑)を示す細胞のおよそのパーセンテージを記録した。結果を、図5に示す。PER.C6−α2,6STが、臨床分離株(白色棒)の複製を有効に支援することは明らかである。
PER.C6及びPER.C6−α2,6STにおけるウイルスの生産を、ウイルスの上清を接種したMDCK(Madin Darbin Canine Kidney)細胞におけるプラークの形成を記録することによって調べた。MDCK細胞は、そのようなプラーク・アッセイ実験に特に有用である。実施例5に記載した方法に従って、PER.C6とPER.C6−α2,6STの両方で増殖させた初代及びPER.C6継代インフルエンザウイルスの10倍希釈したウイルスの上清合計1mlを、95%コンフルエンスとなるまで、6ウェルのプレートで、2mMのL−グルタミンを追加したDMEM内で培養したMDCK細胞に接種した。1時間後、37℃で、細胞をPBSで2回洗浄し、3mlのアガロース混合物(2.5%アガロース 1.2ml、2xMEM 1.5ml 、200mM L−グルタミン 30μl、トリプシン−EDTA 24μl、PBS 250μl)を用いて過負荷をかけた。次に、湿度が高い状態で、10%CO2雰囲気下、37℃で、約3日間、細胞をインキュベートし、ウイルスのプラークを視覚によって記録し、計数した。結果を図6に示す。インフルエンザウイルスの臨床分離株(白色棒)及びPER.C6継代ウイルス(灰色棒)は、PER.C6−α2,6ST細胞に非常に効果的に感染することができたが(右パネル)、PER.C6細胞(左パネル)は、初代臨床分離株による感染に対する感受性があまりなかった。このことは、α2,6シアリルトランスフェラーゼを過剰発現する細胞は、初代ウイルス分離株を増殖させるのに特に有用であることを示し、これらの細胞が、迅速かつ安全な方法で、例えばインフルエンザ感染症対するワクチンを製造するのに非常に有用であることを示している。
新規なFACSによる方法を使用して、上清中のインフルエンザウイルスの力価を測定した。前記方法は、ウイルス複製の最初のラウンド内に生産的に感染している細胞画分を検出することによって、複製能力のあるビリオンを定量することを伴う。0.01から1の間のPER.C6の懸濁培養物及び感染部分を用いて、数時間以内に非常に正確な値を得ることができる。MDCK細胞を用いたプラーク・アッセイによる同様の滴定は、現在のところ、本技術分野で多く用いられているインフルエンザウイルス滴定用の標準的なアッセイであって、該滴定は、はるかに長期に渡り(一般的に大体2週間)、労力を要し、特に再現性が低い。以下に、使用した材料及び方法の専門的な説明をする。ここでは、FACSを用いる上清中のインフルエンザウイルス粒子の滴定のために懸濁細胞を用いることができることを示す。
Baum LG and Paulson JC (1990) Sialyloligosaccharides of the respiratory epithelium in the selection of human influenza virus receptor specificity. Acta Histochem Suppl 40: 35-8.
Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, Krauss S, Shortridge KF and Webster RG (1998) Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351: 472-427.
Couceiro JN, Paulson JC and Baum LG (1993) Influenza virus strains selectively recognize sialyl-oligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity. Virus Res 29: 155-165.
Daniels PS, Jeffries S, Yates P, Schild GC, Rogers GN, Paulson JC, Wharton SA, Douglas AR, Skehel JJ and Wiley DC (1987) The receptor-binding and membrane-fusion pro-perties of influenza virus variants selected using anti-haemagglutinin monoclonal antibodies. Embo J 6: 1459-1465.
Gambaryan AS, Robertson JS and Matrosovich MN (1999) Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses. Virology 258: 232-239.
Gambaryan AS, Tuzikov AB, Piskarev VE, Yamnikova SS, Lvov DK, Robertson JS, Bovin NV and Matrosovich MN (1997) Specification of receptor-binding phenotypes of influenza virus isolates from different hosts using synthetic sialylglycopolymers: non-egg-adapted human H1 and H3 influenza A and influenza B viruses share a common high binding affinity for 6'-sialyl(N-acetyllactosamine). Virology 232: 345-350.
Gibbs MJ, Armstrong JS and Gibbs AJ (2001) Recombination in the hemagglutinin gene of the 1918 "Spanish flu". Science 293: 1842-1845.
Govorkova EA, Matrosovich MN, Tuzikov AB et al. (1999) Selection of receptor-binding variants of human influenza A and B viruses in baby hamster kidney cells. Virology 262: 31- 38.
Hatta M, Gao P, Halfmann P and Kawaoka Y (2001) Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293:1840-1842.
Ilobi CP, Henfrey R, Robertson JS, Mumford JA, Erasmus BJ and Wood JM (1994) Antigenic and molecular characterization of host cell-mediated variants of equine H3N8 influenza viruses. J Gen Virol 75: 669-673.
Ito T, Suzuki Y, Takada A, Kawamoto A, Otsuki K, Masuda H, Yamada M, Suzuki T, Kida H and Kawaoka Y (1997) Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J Virol 71: 3357- 3362.
Liu CK, Wei G, Atwood WJ (1998) Infection of glial cells by the human polyomavirus JC is mediated by an N-linked glycoprotein containing terminal α(2-6)-linked sialic acids. J Virol 72: 4643-4639.
Newman RW, Jennings R, Major DL, Robertson JS, Jenkins R, Potter CW, Burnett I, Jewes L, Anders M, Jackson D and et al. (1993) Immune response of human volunteers and animals to vaccination with egg-grown influenza A (H1N1) virus is influenced by three amino acid substitutions in the haemagglutinin molecule. Vaccine 11: 400-406.
Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M and Uytdehaag F (2001) The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19: 2716-2721.
Potter WP (1998). Chronicle of inflenza pandemics. In Textbook of influenza, NKG, RG Webster and AJ Hay, eds. (Oxford) pp. 3-18.
Robertson JS, Cook P, Nicolson C, Newman R and Wood JM (1994) Mixed populations in influenza virus vaccine strains. Vaccine 12: 1317-1322.
Rogers GN, Daniels RS, Skehel JJ, Wiley DC, Wang XF, Higa HH and Paulson JC (1985) Host-mediated selection of influenza virus receptor variants. Sialic acid-α 2,6 Gal-specific clones of A/duck/Ukraine/1/63 revert to sialic acid-α 2,3 Gal-specific wild type in ovo. J Biol Chem 260: 7362-7367.
Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J, Hemphill M, Rowe T, Shaw M, Xu X, Fukuda K and Cox N (1998) Character-ization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279: 393-396.
Suzuki Y (1994) Gangliosides as influenza virus receptors. Variation of influenza viruses and their recognition of the receptor sialo-sugar chains. Prog Lipid Res 33: 429-457.
Suzuki Y, Kato H, Naeve CW and Webster RG (1989) Singleamino-acid substitution in an antigenic site of influenza virus hemagglutinin can alter the specificity of binding to cell membrane-associated gangliosides. J Virol 63: 4298-4302.
Suzuki T, Portner A, Scroggs RA, Uchikawa M, Koyama N, Matsuo K, Suzuki Y and Takimoto T (2001) Receptor specificities of human respiroviruses. J Virol 75: 4604-4613.
Walters RW, Yi SM, Keshavjee S, Brown KE, Welsh MJ, Chiorini JA and Zabner J (2001) Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 276: 20610-20616.
Claims (19)
- インフルエンザウイルス粒子を生産するための方法であって、
− アデノウイルスのE1で形質転換されたヒト細胞を、培地において、インフルエンザウイルス粒子による前記細胞の感染を促す条件下に、前記インフルエンザウイルス粒子と接触させる工程と、
− 前記細胞を、前記インフルエンザウイルス粒子の増殖を促す条件下に培養する工程と
を含み、
前記細胞は、遺伝子操作によって、α2,6シアリルトランスフェラーゼをコード化する核酸を過剰発現する、方法。 - 前記α2,6シアリルトランスフェラーゼはヒトα2,6シアリルトランスフェラーゼである、請求項1に記載の方法。
- インフルエンザウイルス粒子を生産するための方法であって、
− アデノウイルスのE1で形質転換されたヒト細胞を、培地において、インフルエンザウイルス粒子による前記細胞の感染を促す条件下に、前記インフルエンザウイルス粒子と接触させる工程と、
− 前記細胞を、前記インフルエンザウイルス粒子の増殖を促す条件下に培養する工程と
を含み、
前記細胞は、遺伝子操作によって、α2,3シアリルトランスフェラーゼをコード化する核酸を過剰発現する、方法。 - 前記α2,3シアリルトランスフェラーゼはヒトα2,3シアリルトランスフェラーゼである、請求項3に記載の方法。
- 前記インフルエンザウイルス粒子はインフルエンザ分離株において存在する、請求項1〜4のいずれか1項に記載の方法。
- 前記インフルエンザ分離株は少なくとも1種のインフルエンザに感染した哺乳類対象体から得られる、請求項5に記載の方法。
- 前記インフルエンザに感染した哺乳類対象体はヒト又はブタである、請求項6に記載の方法。
- 前記インフルエンザ分離株は少なくとも1種のインフルエンザに感染したトリから得られる、請求項5に記載の方法。
- 前記ヒト細胞は、ECACCの第96022940号の下で受託されたような細胞であり、α2,6シアリルトランスフェラーゼをコード化する核酸又はα2,3シアリルトランスフェラーゼをコード化する核酸が遺伝子操作によって導入されたものである、請求項1〜8のいずれか1項に記載の方法。
- シアリルトランスフェラーゼをコード化する前記核酸は、前記細胞には異種である、請求項1〜9のいずれか1項に記載の方法。
- シアリルトランスフェラーゼをコード化する前記核酸は、前記細胞のゲノムに組み込まれる、請求項10に記載の方法。
- ワクチンを製造するための方法であって、
− 請求項1〜11のいずれか1項に記載のインフルエンザウイルス粒子を生産する工程と、
− そのように生産されたインフルエンザウイルス粒子を不活性化する工程と
を含む、方法。 - 前記方法は、さらに、
− そのように生産されたインフルエンザウイルス粒子を処理して抗原性部分を生成する工程と、
− 少なくとも1種の抗原性部分を得る工程と
を含む、請求項12に記載の方法。 - 前記抗原性部分は、インフルエンザウイルス由来の、血球凝集素タンパク質及び/又はノイラミニダーゼタンパク質を包含する、請求項13に記載の方法。
- アデノウイルスのE1で形質転換されたヒト細胞の使用であって、インフルエンザウイルス粒子を増殖させるために、α2,6シアリルトランスフェラーゼを遺伝子操作によって過剰発現させる、ヒト細胞の使用。
- アデノウイルスのE1で形質転換されたヒト細胞の使用であって、インフルエンザウイルス粒子を増殖させるために、α2,3シアリルトランスフェラーゼを遺伝子操作によって過剰発現させる、ヒト細胞の使用。
- 前記インフルエンザウイルス粒子は、少なくとも1種のインフルエンザに感染した哺乳類対象体から得られたインフルエンザ分離株において存在する、請求項15又は16に記載の使用。
- 前記インフルエンザに感染した哺乳類対象体はヒト又はブタである、請求項17に記載の使用。
- 前記インフルエンザウイルス粒子は、少なくとも1種のインフルエンザに感染したトリから得られたインフルエンザ分離株において存在する、請求項18に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/NL2001/000892 WO2003048197A1 (en) | 2001-12-07 | 2001-12-07 | Production and of viruses, viral isolates and vaccines |
EP02075327 | 2002-01-25 | ||
PCT/NL2002/000804 WO2003048348A2 (en) | 2001-12-07 | 2002-12-09 | Production of viruses, viral isolates and vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005511051A JP2005511051A (ja) | 2005-04-28 |
JP4480398B2 true JP4480398B2 (ja) | 2010-06-16 |
Family
ID=26077595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003549527A Expired - Lifetime JP4480398B2 (ja) | 2001-12-07 | 2002-12-09 | ウイルス、ウイルス分離株及びワクチンの製造方法 |
Country Status (13)
Country | Link |
---|---|
US (2) | US7504248B2 (ja) |
EP (1) | EP1465987B1 (ja) |
JP (1) | JP4480398B2 (ja) |
KR (1) | KR100979025B1 (ja) |
CN (1) | CN100547069C (ja) |
AT (1) | ATE384785T1 (ja) |
AU (1) | AU2002351444B2 (ja) |
CA (1) | CA2468957C (ja) |
DE (1) | DE60224843T2 (ja) |
ES (1) | ES2297028T3 (ja) |
NZ (1) | NZ533124A (ja) |
PT (1) | PT1465987E (ja) |
WO (1) | WO2003048348A2 (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
IL122614A0 (en) | 1995-06-15 | 1998-08-16 | Introgene Bv | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US20050164386A1 (en) * | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US7521220B2 (en) * | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
ATE384785T1 (de) | 2001-12-07 | 2008-02-15 | Crucell Holland Bv | Herstellung von viren, virusisolaten, und impfstoffen |
WO2004055187A1 (en) | 2002-12-17 | 2004-07-01 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
DK1623023T3 (da) | 2003-05-09 | 2009-03-02 | Crucell Holland Bv | Kulturer af E1-immortaliserede celler og fremgangsmåder til dyrkning deraf til forögelse af produktudbytter derfra |
US8506967B2 (en) | 2003-07-11 | 2013-08-13 | Novavax, Inc. | Functional influenza virus like particles (VLPs) |
US8592197B2 (en) * | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
US8992939B2 (en) | 2003-07-11 | 2015-03-31 | Novavax, Inc. | Highly efficient influenza matrix (M1) proteins |
US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
KR20070104881A (ko) * | 2004-10-14 | 2007-10-29 | 크루셀 홀란드 비.브이. | 말라리아 프라임/부스트 백신 |
AU2005322353B2 (en) * | 2004-12-23 | 2011-09-01 | Medimmune, Llc | Non-tumorigenic MDCK cell line for propagating viruses |
CN103361319A (zh) | 2006-09-15 | 2013-10-23 | 米迪缪尼有限公司 | 支持病毒生长到高效价的mdck细胞系和采用该细胞系的生物反应器方法 |
US8187853B2 (en) * | 2007-03-02 | 2012-05-29 | Japan Tobacco Inc. | β-galactoside-α2,6-sialyltransferase, a gene encoding thereof, and a method for enhancing enzyme activity |
US20120039939A1 (en) * | 2008-04-11 | 2012-02-16 | The Johns Hopkins University | Compositions and methods for vaccine and virus production |
TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
US8163523B2 (en) * | 2008-06-11 | 2012-04-24 | Flugen, Inc. | Cell-based systems for producing influenza vaccines |
CN103952376A (zh) | 2008-09-24 | 2014-07-30 | 米迪缪尼有限公司 | 培养细胞、增殖和纯化病毒的方法 |
ES2559007T3 (es) * | 2009-04-23 | 2016-02-10 | Crucell Holland B.V. | Alfa1 antitripsina humana recombinante |
GB2471093A (en) | 2009-06-17 | 2010-12-22 | Cilian Ag | Viral protein expression in ciliates |
CN102559599A (zh) * | 2010-12-08 | 2012-07-11 | 吉林大学 | Vero-SIAT1细胞系及其应用 |
CN102175849B (zh) * | 2010-12-22 | 2013-07-03 | 江苏出入境检验检疫局动植物与食品检测中心 | 一种快速检测猪瘟抗体的试剂盒及其制备方法 |
CA2817765A1 (en) * | 2011-01-06 | 2012-07-12 | The Johns Hopkins University | Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
FR2573436B1 (fr) | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin |
US4835260A (en) * | 1987-03-20 | 1989-05-30 | Genetics Institute, Inc. | Erythropoietin composition |
US5192539A (en) * | 1988-07-21 | 1993-03-09 | Akzo N.V. | Infectious bursal disease virus production in continuous cell lines |
US5047335A (en) * | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
GB8900483D0 (en) * | 1989-01-10 | 1989-03-08 | Celltech Ltd | Recombinant dna method |
DE3923963A1 (de) * | 1989-07-20 | 1991-01-31 | Behringwerke Ag | Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung |
US5856298A (en) * | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
EP0596881B1 (fr) | 1991-08-01 | 1997-03-19 | Fondation Nationale De Transfusion Sanguine | Expression dans des lignees lymphoblastoides humaines non-tumorales avec un vecteur integratif |
US5384249A (en) * | 1991-12-17 | 1995-01-24 | Kyowa Hakko Kogyo Co., Ltd. | α2→3 sialyltransferase |
IL110669A (en) | 1993-08-17 | 2008-11-26 | Kirin Amgen Inc | Erythropoietin analogs |
US5733782A (en) * | 1993-10-25 | 1998-03-31 | Creative Biomolecules, Inc. | Methods and compositions for high protein production from non-native DNA |
US5830851A (en) * | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
US5773569A (en) * | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5789247A (en) * | 1994-04-01 | 1998-08-04 | Ballay; Annick | Expression in non-tumoral human lymphoblastoid lines with an integrative vector |
US5610043A (en) | 1994-04-28 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (AD12/SV40) hybrid virus |
US5767078A (en) * | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
IL122614A0 (en) * | 1995-06-15 | 1998-08-16 | Introgene Bv | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US5989805A (en) | 1995-10-27 | 1999-11-23 | Board Of Trustees Operating Michigan State University | Immortal avian cell line to grow avian and animal viruses to produce vaccines |
CN100390290C (zh) * | 1995-11-13 | 2008-05-28 | 宝生物工程株式会社 | 用逆转录病毒将基因转入靶细胞的方法 |
US5835382A (en) * | 1996-04-26 | 1998-11-10 | The Scripps Research Institute | Small molecule mimetics of erythropoietin |
BR9712675A (pt) | 1996-10-25 | 1999-10-19 | Searle & Co | Agonistas do receptor de eritropoietina circularmente permutados. |
JP2000509614A (ja) | 1997-03-04 | 2000-08-02 | バクスター インターナショナル インコーポレイテッド | アデノウイルスe1−相補性細胞系 |
AU736334B2 (en) | 1997-03-27 | 2001-07-26 | University Of British Columbia, The | Insect expression vectors |
CA2221819A1 (en) * | 1997-03-27 | 1998-09-27 | Thomas A. Gigliatti | Insect expression vectors |
ATE341625T1 (de) | 1997-07-23 | 2006-10-15 | Roche Diagnostics Gmbh | Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren |
US6670188B1 (en) * | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
AU4682999A (en) * | 1998-06-16 | 2000-01-05 | Human Genome Sciences, Inc. | 94 human secreted proteins |
NZ514690A (en) | 1999-04-13 | 2004-07-30 | Kenneth S | Modulation of excitable tissue function by peripherally administered erythropoietin |
DK2163640T3 (da) | 1999-04-15 | 2012-03-05 | Crucell Holland Bv | Rekombinant proteinproduktion i en human celle indeholdende mindst ét E1-protein af adenovirus |
WO2003048197A1 (en) * | 2001-12-07 | 2003-06-12 | Crucell Holland B.V. | Production and of viruses, viral isolates and vaccines |
US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US7297680B2 (en) * | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US20050164386A1 (en) * | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6558948B1 (en) * | 1999-11-23 | 2003-05-06 | Stefan Kochanek | Permanent amniocytic cell line, its production and use for the production of gene transfer vectors |
US7521220B2 (en) * | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
EP1103610A1 (en) * | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
CA2465007C (en) * | 2001-10-29 | 2012-01-17 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
ATE384785T1 (de) * | 2001-12-07 | 2008-02-15 | Crucell Holland Bv | Herstellung von viren, virusisolaten, und impfstoffen |
NZ533332A (en) | 2001-12-17 | 2005-07-29 | Crucell Holland B | Efficient production of F(AB')2 fragments in mammalian cells |
EP1552298A4 (en) | 2002-07-01 | 2006-11-08 | Kenneth S Warren Inst Inc | RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF |
EP1553983A2 (en) * | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
WO2004055187A1 (en) * | 2002-12-17 | 2004-07-01 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
DK1623023T3 (da) | 2003-05-09 | 2009-03-02 | Crucell Holland Bv | Kulturer af E1-immortaliserede celler og fremgangsmåder til dyrkning deraf til forögelse af produktudbytter derfra |
KR20070104881A (ko) * | 2004-10-14 | 2007-10-29 | 크루셀 홀란드 비.브이. | 말라리아 프라임/부스트 백신 |
-
2002
- 2002-12-09 AT AT02786227T patent/ATE384785T1/de active
- 2002-12-09 CN CNB028243633A patent/CN100547069C/zh not_active Expired - Fee Related
- 2002-12-09 US US10/497,832 patent/US7504248B2/en not_active Expired - Lifetime
- 2002-12-09 JP JP2003549527A patent/JP4480398B2/ja not_active Expired - Lifetime
- 2002-12-09 CA CA2468957A patent/CA2468957C/en not_active Expired - Lifetime
- 2002-12-09 AU AU2002351444A patent/AU2002351444B2/en not_active Ceased
- 2002-12-09 EP EP02786227A patent/EP1465987B1/en not_active Expired - Lifetime
- 2002-12-09 DE DE60224843T patent/DE60224843T2/de not_active Expired - Lifetime
- 2002-12-09 NZ NZ533124A patent/NZ533124A/en not_active IP Right Cessation
- 2002-12-09 ES ES02786227T patent/ES2297028T3/es not_active Expired - Lifetime
- 2002-12-09 PT PT02786227T patent/PT1465987E/pt unknown
- 2002-12-09 KR KR1020047008520A patent/KR100979025B1/ko active IP Right Grant
- 2002-12-09 WO PCT/NL2002/000804 patent/WO2003048348A2/en active IP Right Grant
-
2007
- 2007-07-16 US US11/879,422 patent/US8802417B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2002351444A1 (en) | 2003-06-17 |
PT1465987E (pt) | 2008-04-15 |
US7504248B2 (en) | 2009-03-17 |
WO2003048348A2 (en) | 2003-06-12 |
EP1465987A2 (en) | 2004-10-13 |
AU2002351444B2 (en) | 2008-02-21 |
KR20050044677A (ko) | 2005-05-12 |
US8802417B2 (en) | 2014-08-12 |
US20080050403A1 (en) | 2008-02-28 |
ES2297028T3 (es) | 2008-05-01 |
CA2468957A1 (en) | 2003-06-12 |
KR100979025B1 (ko) | 2010-08-30 |
DE60224843D1 (de) | 2008-03-13 |
CN100547069C (zh) | 2009-10-07 |
JP2005511051A (ja) | 2005-04-28 |
CN1599794A (zh) | 2005-03-23 |
EP1465987B1 (en) | 2008-01-23 |
NZ533124A (en) | 2005-11-25 |
CA2468957C (en) | 2011-07-12 |
DE60224843T2 (de) | 2009-01-08 |
US20050123564A1 (en) | 2005-06-09 |
ATE384785T1 (de) | 2008-02-15 |
WO2003048348A3 (en) | 2003-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4480398B2 (ja) | ウイルス、ウイルス分離株及びワクチンの製造方法 | |
JP6352974B2 (ja) | ワクチンのための高力価組み換えインフルエンザ・ウィルス | |
JP4331432B2 (ja) | ワクチンの生成方法 | |
US7521220B2 (en) | Production of vaccines | |
US7527961B2 (en) | Production of vaccines | |
US8163523B2 (en) | Cell-based systems for producing influenza vaccines | |
Hu et al. | HA stabilization promotes replication and transmission of swine H1N1 gamma influenza viruses in ferrets | |
WO2003048197A1 (en) | Production and of viruses, viral isolates and vaccines | |
US20140377308A1 (en) | METHOD FOR PRODUCTION OF pH STABLE ENVELOPED VIRUSES | |
Marzio et al. | Production of viruses, viral isolates and vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080916 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091027 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100127 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100309 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100316 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130326 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4480398 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130326 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140326 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |